Discontinuation of Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis and Excellent Disease Control

Siri Lillegraven,Nina Paulshus Sundlisaeter,Anna-Birgitte Aga,Joseph Sexton,Daniel H. Solomon,Desiree van der Heijde,Espen A. Haavardsholm

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION（2023）

引用 1|浏览1

暂无评分

摘要

This open-label randomized clinical trial assessed the 12-month risk of disease activity flares after discontinuation of conventional synthetic DMARDs (csDMARDs) compared with continuing half-dose csDMARDs in adult Norwegian patients with rheumatoid arthritis and excellent disease control.

查看译文

关键词

antirheumatic drugs,rheumatoid arthritis,excellent disease-modifying control

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要